VIDEO: Studies show faricimab reduces risk for epiretinal membrane formation

ByJeffrey R. Willis, MD, PhD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Jeffrey R. Willis, MD, PhD, discusses the impact of faricimab vs. aflibercept on epiretinal membrane formation in eyes with diabetic macular edema.

The post hoc analysis used data from the phase 3 YOSEMITE and RHINE studies and also looked at the impact of epiretinal membranes (ERMs) on vision, anatomy and treatment durability, according to Willis.

“Our studies showed that faricimab every 8 weeks reduced the risk of ERM formation by 52% compared to aflibercept every 8 weeks,” he said. “We also showed that ERMs potentially have an impact on vision anatomy and treatment durability.”

Published by:

Sources/Disclosures

Collapse

Source:

Jaffe G. Impact of faricimab vs aflibercept on epiretinal membrane formation over 2 years in eyes with DME in the YOSEMITE/RHINE phase 3 trials. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.

Disclosures: Willis reports being global development leader for Vabysmo at Genentech/Roche.

American Society of Retina Specialists Meeting

Read more

VIDEO: Studies show faricimab reduces risk for epiretinal membrane formation

Related Content